Novo Nordisk A\/S Beat Expectations

Novo Nordisk A\/S (NVO) reported earnings of $0.97 per share on revenue of $11.69 billion for the second quarter ended June 2025. The consensus earnings estimate was $0.93 per share on revenue of $11.79 billion. The Earnings Whisper number was $0.92 per share. The company beat expectations by 5.43% while revenue grew 19.00% on a year-over-year basis.

Novo-Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes care and biopharmaceuticals.